Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Urovant Sciences Ltd. (UROV) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/29/2021 8-K Appointed a new director
Docs: "Amended and Restated Memorandum of Association of Urovant Sciences Ltd",
"Amended and Restated Bye-laws of Urovant Sciences Ltd",
"Sumitovant Biopharma Completes Acquisition of Urovant Sciences"
03/24/2021 8-K Submission of Matters to a Vote of Security Holders, Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 23, 2021 Urovant Sciences Ltd. Bermuda 001-38667 98-1463899 Suite 1, 3rd Floor 11-12 St. James's Square London SW1Y 4LB United Kingdom Not Applicable +44 207 400 3347 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-comm..."
02/12/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
02/09/2021 8-K Quarterly results
12/23/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Urovant Sciences Announces U.S. FDA Approval of GEMTESA ® 75 mg Tablets for the Treatment of Patients with Overactive Bladder"
11/24/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 24, 2020 Urovant Sciences Ltd. Bermuda 001-38667 98-1463899 Suite 1, 3rd Floor 11-12 St. James's Square London SW1Y 4LB United Kingdom Not Applicable +44 207 400 3347 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome Pain Did Not Meet Primary Endpoint"
11/17/2020 8-K Regulation FD Disclosure
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 17, 2020 Urovant Sciences Ltd. Bermuda 001-38667 98-1463899 Suite 1, 3rd Floor 11-12 St. James's Square London SW1Y 4LB United Kingdom Not Applicable +44 207 400 3347 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c..."
11/02/2020 8-K Quarterly results
Docs: "Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results"
10/07/2020 8-K Quarterly results
09/23/2020 8-K Quarterly results
08/13/2020 8-K Quarterly results
06/18/2020 8-K Quarterly results
06/18/2020 8-K Quarterly results
06/02/2020 8-K Investor presentation
Docs: "Investor Presentation dated June 2020"
05/28/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Information Sharing and Cooperation Agreement, by and between Urovant Sciences, Ltd. and Sumitovant Biopharma Ltd"
05/27/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "James Hindman, a veteran global and strategic senior financial executive, brings extensive experience in the pharmaceutical, biologics and medical device industries to the Urovant Board • Mr. Hindman most recently served as Chief Financial Officer at Allergan until its $70.5B sale to Actavis"
04/06/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Indemnification Agreement with officers and directors",
"Form of Indemnification Agreement with officers and directors"
03/23/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 19, 2020 Urovant Sciences Ltd. Bermuda 001-38667 98-1463899 Suite 1, 3rd Floor 11-12 St. James's Square London SW1Y 4LB United Kingdom Not Applicable +44 207 400 3347 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-comm...",
"Separation and Consulting Agreement, by and between Keith A. Katkin and Urovant Sciences, Inc",
"Employment Agreement, by and between James A. Robinson and Urovant Sciences, Inc",
"Urovant Sciences Appoints James Robinson as President and Chief Executive Officer"
02/13/2020 8-K Quarterly results
Docs: "Urovant Sciences Reports 2019 Third Fiscal Quarter Financial Results"
01/09/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 6, 2020 Urovant Sciences Ltd. Bermuda 001-38667 98-1463899 Suite 1, 3rd Floor 11-12 St. James's Square London SW1Y 4LB United Kingdom Not Applicable +44 207 400 3347 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-com..."
01/08/2020 8-K Quarterly results
12/30/2019 8-K Quarterly results
11/05/2019 8-K Quarterly results
10/31/2019 8-K Quarterly results
09/25/2019 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister...
Docs: "Warrant Agreement, issued to Hercules Capital, Inc"
09/17/2019 8-K Quarterly results
08/13/2019 8-K Quarterly results
06/14/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company’s intent, belief or expectations and can be identified by words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “to be,” “will,” “would,” or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identifying words. In this press release, forward-looking statements incl..."
05/13/2019 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Corporate Presentation"
03/20/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder"
03/06/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/22/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Warrant Agreement, issued to Hercules Capital, Inc",
"Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital"
02/13/2019 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy